Weight Loss Drug, Contrave, Rejected By FDA

DIET DRUG REJECTED: The Food and Drug Administration has declined to approve an experimental weight loss drug called Contrave, a surprising rejection to what many analysts expected to be the first new diet drug in a decade.

QUESTIONS OF THE HEART: The FDA asked Contrave to conduct an additional study focused on the drug's heart side effects, a long-standing safety issue with weight loss medications.

FUTURE UNCERTAIN: FDA's request sent shares of drugmaker Orexigen Therapeutics tumbling. Orexigen Therapeutic said the company would have to raise additional money to complete the study, which would likely take years to conduct.